{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:58:53Z","timestamp":1787630333165,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82161138022"],"award-info":[{"award-number":["82161138022"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Pujiang Young Rheumatologists Training Program","award":["SPROG2205"],"award-info":[{"award-number":["SPROG2205"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10067-025-07433-9","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T09:16:33Z","timestamp":1747473393000},"page":"2861-2871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["BAricitinib in patients with SystemIC Sclerosis (BASICS): a prospective, open-label, randomised trial"],"prefix":"10.1007","volume":"44","author":[{"given":"Fangfang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minrui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shucong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaihua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hejian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4575-9243","authenticated-orcid":false,"given":"Yu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"issue":"10103","key":"7433_CR1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685\u20131699","journal-title":"Lancet"},{"issue":"2","key":"7433_CR2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e32834ff2e8","volume":"24","author":"J Barnes","year":"2012","unstructured":"Barnes J, Mayes MD (2012) Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 24(2):165\u2013170","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"7433_CR3","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","volume":"60","author":"M Bairkdar","year":"2021","unstructured":"Bairkdar M et al (2021) Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford) 60(7):3121\u20133133","journal-title":"Rheumatology (Oxford)"},{"issue":"19","key":"7433_CR4","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19):1989\u20132003","journal-title":"N Engl J Med"},{"issue":"3","key":"7433_CR5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas A et al (2020) Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 8(3):304\u2013320","journal-title":"Lancet Respir Med"},{"issue":"6","key":"7433_CR6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 66(6):754\u2013763","journal-title":"Ann Rheum Dis"},{"key":"7433_CR7","doi-asserted-by":"crossref","unstructured":"Jerjen R et al (2022) Systemic sclerosis in adults. Part II: management and therapeutics. J Am Acad Dermatol 87(5):957\u2013978","DOI":"10.1016\/j.jaad.2021.10.066"},{"issue":"7","key":"7433_CR8","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata S et al (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 3(7):e489\u2013e497","journal-title":"Lancet Rheumatol"},{"issue":"Suppl 2","key":"7433_CR9","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O'Shea","year":"2013","unstructured":"O\u2019Shea JJ et al (2013) Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72(Suppl 2):ii111-5","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7433_CR10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC et al (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74(2):333\u2013340","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7433_CR11","first-page":"504","volume":"43","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y et al (2016) Efficacy and safety of baricitinib in japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind. Randomized Placebo-controlled Study J Rheumatol 43(3):504\u2013511","journal-title":"Randomized Placebo-controlled Study J Rheumatol"},{"issue":"5","key":"7433_CR12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68(5):620\u2013628","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"7433_CR13","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2016-210911","volume":"76","author":"Y Zhang","year":"2017","unstructured":"Zhang Y et al (2017) JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. Ann Rheum Dis 76(8):1467\u20131475","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7433_CR14","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","volume":"64","author":"C Dees","year":"2012","unstructured":"Dees C et al (2012) JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis. Arthritis Rheum 64(9):3006\u20133015","journal-title":"Arthritis Rheum"},{"issue":"12","key":"7433_CR15","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K et al (2020) Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156(12):1333\u20131343","journal-title":"JAMA Dermatol"},{"issue":"1","key":"7433_CR16","doi-asserted-by":"crossref","first-page":"e000424","DOI":"10.1136\/lupus-2020-000424","volume":"7","author":"T Dorner","year":"2020","unstructured":"Dorner T et al (2020) Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med 7(1):e000424","journal-title":"Lupus Sci Med"},{"issue":"11","key":"7433_CR17","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis 72(11):1747\u20131755","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"7433_CR18","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28(7):1573\u20131576","journal-title":"J Rheumatol"},{"issue":"1","key":"7433_CR19","first-page":"84","volume":"25","author":"DE Furst","year":"1998","unstructured":"Furst DE et al (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25(1):84\u201388","journal-title":"J Rheumatol"},{"issue":"10","key":"7433_CR20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D et al (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8(10):963\u2013974","journal-title":"Lancet Respir Med"},{"issue":"5","key":"7433_CR21","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","volume":"79","author":"D Khanna","year":"2020","unstructured":"Khanna D et al (2020) Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis 79(5):618\u2013625","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7433_CR22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna D et al (2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 77(2):212\u2013220","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7433_CR23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","volume":"80","author":"D Khanna","year":"2021","unstructured":"Khanna D et al (2021) New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American college of rheumatology composite response index in systemic sclerosis. Ann Rheum Dis 80(5):641\u2013650","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7433_CR24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-019-1919-6","volume":"21","author":"KM Matsuda","year":"2019","unstructured":"Matsuda KM et al (2019) Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study. Arthritis Res Ther 21(1):129","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"7433_CR25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/acr.22804","volume":"68","author":"D Khanna","year":"2016","unstructured":"Khanna D et al (2016) The american college of rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Care Res (Hoboken) 68(2):167\u2013178","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"7433_CR26","doi-asserted-by":"crossref","first-page":"103168","DOI":"10.1016\/j.autrev.2022.103168","volume":"21","author":"C Moriana","year":"2022","unstructured":"Moriana C et al (2022) JAK inhibitors and systemic sclerosis: a systematic review of the literature. Autoimmun Rev 21(10):103168","journal-title":"Autoimmun Rev"},{"key":"7433_CR27","doi-asserted-by":"crossref","unstructured":"Zhang L et al (2022) The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - a network meta-analysis. J Eur Acad Dermatol Venereol 36(11):1937\u20131946","DOI":"10.1111\/jdv.18263"},{"issue":"6","key":"7433_CR28","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","volume":"174","author":"KA Papp","year":"2016","unstructured":"Papp KA et al (2016) A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 174(6):1266\u20131276","journal-title":"Br J Dermatol"},{"issue":"13","key":"7433_CR29","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374(13):1243\u20131252","journal-title":"N Engl J Med"},{"issue":"12","key":"7433_CR30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM et al (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discovery 16(12):843\u2013862","journal-title":"Nat Rev Drug Discovery"},{"issue":"10381","key":"7433_CR31","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401(10381):1011\u20131019","journal-title":"Lancet"},{"issue":"10381","key":"7433_CR32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 401(10381):1001\u20131010","journal-title":"Lancet"},{"issue":"10038","key":"7433_CR33","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D et al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387(10038):2630\u20132640","journal-title":"Lancet"},{"issue":"12","key":"7433_CR34","first-page":"2101","volume":"12","author":"E Fiorentini","year":"2022","unstructured":"Fiorentini E et al (2022) Potential role of jak inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data. Life (Basel, Switzerland) 12(12):2101","journal-title":"Life (Basel, Switzerland)"},{"issue":"1","key":"7433_CR35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","volume":"72","author":"D Khanna","year":"2020","unstructured":"Khanna D et al (2020) Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase ii investigator-initiated, multicenter, double-blind, randomized. Placebo-Control Trial Arthritis Rheumatol 72(1):125\u2013136","journal-title":"Placebo-Control Trial Arthritis Rheumatol"},{"issue":"8","key":"7433_CR36","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","volume":"72","author":"R Spiera","year":"2020","unstructured":"Spiera R et al (2020) Safety and efficacy of Lenabasum in a phase ii, randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheumatol (Hoboken, NJ) 72(8):1350\u20131360","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"2","key":"7433_CR37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","volume":"68","author":"D Khanna","year":"2016","unstructured":"Khanna D et al (2016) The american college of rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol (Hoboken, NJ) 68(2):299\u2013311","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"7433_CR38","first-page":"S247","volume":"176","author":"SPH Alexander","year":"2019","unstructured":"Alexander SPH et al (2019) The concise guide to pharmacology 2019\/20: catalytic receptors. Br J Pharmacol 176:S247\u2013S296","journal-title":"Br J Pharmacol"},{"key":"7433_CR39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2016.05.004","volume":"42","author":"C Hardman","year":"2016","unstructured":"Hardman C, Ogg G (2016) Interleukin-33, friend and foe in type-2 immune responses. Curr Opin Immunol 42:16\u201324","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"7433_CR40","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/ard.2009.119321","volume":"69","author":"M Manetti","year":"2010","unstructured":"Manetti M et al (2010) The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 69(3):598\u2013605","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7433_CR41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/annrheumdis-2012-201553","volume":"72","author":"S Terras","year":"2013","unstructured":"Terras S et al (2013) Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis. Ann Rheum Dis 72(1):144\u2013145","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"7433_CR42","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1136\/ard.2010.148247","volume":"70","author":"M Manetti","year":"2011","unstructured":"Manetti M et al (2011) Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Ann Rheum Dis 70(10):1876\u20131878","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7433_CR43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/sji.12317","volume":"82","author":"A Wagner","year":"2015","unstructured":"Wagner A et al (2015) Increased serum levels of the IL-33 neutralizing sST2 in limited cutaneous systemic sclerosis. Scand J Immunol 82(3):269\u2013274","journal-title":"Scand J Immunol"},{"issue":"2","key":"7433_CR44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0014-5793(95)01430-6","volume":"378","author":"OJ Kwon","year":"1996","unstructured":"Kwon OJ et al (1996) Identification of a novel protein containing two C2 domains selectively expressed in the rat brain and kidney. FEBS Lett 378(2):135\u2013139","journal-title":"FEBS Lett"},{"issue":"10","key":"7433_CR45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/intimm\/dxaa032","volume":"32","author":"Y Takada","year":"2020","unstructured":"Takada Y et al (2020) Increased urinary exosomal SYT17 levels in chronic active antibody-mediated rejection after kidney transplantation via the IL-6 amplifier. Int Immunol 32(10):653\u2013662","journal-title":"Int Immunol"},{"issue":"4","key":"7433_CR46","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.immuni.2008.07.018","volume":"29","author":"H Ogura","year":"2008","unstructured":"Ogura H et al (2008) Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29(4):628\u2013636","journal-title":"Immunity"},{"issue":"1","key":"7433_CR47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/0008-5472.CAN-13-2322","volume":"74","author":"T Atsumi","year":"2014","unstructured":"Atsumi T et al (2014) Inflammation amplifier, a new paradigm in cancer biology. Cancer Res 74(1):8\u201314","journal-title":"Cancer Res"},{"issue":"5","key":"7433_CR48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1615\/CritRevImmunol.v35.i5.20","volume":"35","author":"I Nakagawa","year":"2015","unstructured":"Nakagawa I et al (2015) Role of inflammation amplifier-induced growth factor expression in the development of inflammatory diseases. Crit Rev Immunol 35(5):365\u2013378","journal-title":"Crit Rev Immunol"},{"issue":"1","key":"7433_CR49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1084\/jem.20100900","volume":"208","author":"M Murakami","year":"2011","unstructured":"Murakami M et al (2011) Local microbleeding facilitates IL-6- and IL-17-dependent arthritis in the absence of tissue antigen recognition by activated T cells. J Exp Med 208(1):103\u2013114","journal-title":"J Exp Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07433-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07433-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07433-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:46:38Z","timestamp":1751874398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07433-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7433"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07433-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial (ChiCTR 2100041982) was approved by the Ethics Committee of Huashan Hospital, Fudan University (approval No. 2021\u2013470). All participating patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}